Home > Cardiology > AHA 2019 > Challenges in Heart Failure Management > FUEL trial: Udenafil improves some exercise measurements in Fontan

FUEL trial: Udenafil improves some exercise measurements in Fontan

Presented By
Dr David Goldberg, Children’s Hospital of Philadelphia, USA
Conference
AHA 2019
Trial
FUEL

In The Fontan Udenafil Exercise Longitudinal Trial (FUEL), udenafil treatment was not associated with an improvement in oxygen consumption at peak exercise in patients with Fontan physiology; however, multiple measures of exercise performance at the ventilatory anaerobic threshold did show marked improvements.

Dr David Goldberg (Children’s Hospital of Philadelphia, USA) presented the 30-centre phase 3 clinical trial that attempted to address a problem resulting from the Fontan physiology, which can lead to deterioration of cardiovascular efficiency associated with a decline in exercise performance [1]. The researchers hypothesised that udenafil may improve exercise performance. The primacy efficacy endpoint of this study was a between-group difference in the change in oxygen consumption (VO2) from baseline to 26 weeks at peak exercise. Key secondary endpoints included myocardial performance index, exerc...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on